|
1
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ambudkar SV, Dey S, Hrycyna CA,
Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular,
and pharmacological aspects of the multidrug transporter. Annu Rev
Pharmacol Toxicol. 39:361–398. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kohno K, Sato S, Uchiumi T, Takano H,
Tanimura H, Miyazaki M, Matsuo K, Hidaka K and Kuwano M: Activation
of the human multidrug resistance 1 (MDR1) gene promoter in
response to inhibitors of DNA topoisomerases. Int J Oncol. 1:73–77.
1992.PubMed/NCBI
|
|
4
|
Uchiumi T, Kohno K, Tanimura H, Matsuo K,
Sato S, Uchida Y and Kuwano M: Enhanced expression of the human
multidrug resistance 1 gene in response to UV light irradiation.
Cell Growth Differ. 4:147–157. 1993.PubMed/NCBI
|
|
5
|
Stein U, Jürchott K, Walther W, Bergmann
S, Schlag PM and Royer HD: Hyperthermia-induced nuclear
translocation of transcription factor YB-1 leads to enhanced
expression of multidrug resistance-related ABC transporters. J Biol
Chem. 276:28562–28569. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi
T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, et al: The
role of nuclear Y-box binding protein 1 as a global marker in drug
resistance. Mol Cancer Ther. 3:1485–1492. 2004.PubMed/NCBI
|
|
7
|
Ogretmen B and Safa AR: Identification and
characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in
the multidrug resistant HL60/VCR human acute myeloid leukemia cell
line. Biochemistry. 39:194–204. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vaiman AV, Stromskaya TP, Rybalkina EY,
Sorokin AV, Guryanov SG, Zabotina TN, Mechetner EB, Ovchinnikov LP
and Stavrovskaya AA: Intracellular localization and content of YB-1
protein in multidrug resistant tumor cells. Biochemistry (Mosc).
71:146–154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bargou RC, Jürchott K, Wagener C, Bergmann
S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B
and Royer HD: Nuclear localization and increased levels of
transcription factor YB-1 in primary human breast cancers are
associated with intrinsic MDR1 gene expression. Nat Med. 3:447–450.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujita T, Ito K, Izumi H, Kimura M, Sano
M, Nakagomi H, Maeno K, Hama Y, Shingu K, Tsuchiya S, et al:
Increased nuclear localization of transcription factor Y-box
binding protein 1 accompanied by up-regulation of P-gp in breast
cancer pretreated with paclitaxel. Clin Cancer Res. 11:8837–8844.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saji H, Toi M, Saji S, Koike M, Kohno K
and Kuwano M: Nuclear expression of YB-1 protein correlates with
P-glycoprotein expression in human breast carcinoma. Cancer Lett.
190:191–197. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cole SP, Bhardwaj G, Gerlach JH, Mackie
JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and
Deeley RG: Overexpression of a transporter gene in a
multidrug-resistant human lung cancer cell line. Science.
258:1650–1654. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaszubiak A, Kupstat A, Müller U, Hausmann
R, Holm PS and Lage H: Regulation of MDR1 gene expression in
multidrug-resistant cancer cells is independent from YB-1. Biochem
Biophys Res Commun. 357:295–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chan CO, Jin DP, Dong NP, Chen SB and Mok
DK: Qualitative and quantitative analysis of chemical constituents
of Centipeda minima by HPLC-QTOF-MA& HPLC-DAD. J Pharm
Biomed Anal. 125:400–407. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taylor RS and Towers GH: Antibacterial
constituents of the Nepalese medicinal herb, Centipeda
minima. Phytochemistry. 47:631–634. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li CL, Wu HZ, Huang YP, Yang YF, Liu YW
and Liu JW: Brevilin A induces apoptosis through a
mitochondrial/caspase and NF-κB pathway in human leukemia HL-60
cells. Biomed Pharmacother. 62:401–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu YQ, Wang XL, Cheng X, Lu YZ, Wang GZ,
Li XC, Zhang J, Wen ZS, Huang ZL, Gao QL, et al: Skp1 in lung
cancer: Clinical significance and therapeutic efficacy of its small
molecule inhibitors. Oncotarget. 6:34953–34967. 2015.PubMed/NCBI
|
|
18
|
Liu Y, Chen XQ, Liang HX, Zhang FX, Zhang
B, Jin J, Chen YL, Cheng YX and Zhou GB: Small compound
6-O-angeloylplenolin induces mitotic arrest and exhibits
therapeutic potentials in multiple myeloma. PLoS One. 6:e219302011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muñoz-Martínez F, Lu P, Cortés-Selva F,
Pérez-Victoria JM, Jiménez IA, Ravelo AG, Sharom FJ, Gamarro F and
Castanys S: Celastraceae sesquiterpenes as a new class of
modulators that bind specifically to human P-glycoprotein and
reverse cellular multidrug resistance. Cancer Res. 64:7130–7138.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mosman T: Rapid colorimetric assay for
cellular growth and survival, application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Q, Wei DZ and Liu JW: In vivo
reversal of doxorubicin resistance by (−)-epigallocatechin gallate
in a solid human carcinoma xenograft. Cancer Lett. 208:179–186.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
National Pharmacopoeia Committee: National
Pharmacopoeia Committee Pharmacopoeia of the People's Republic of
China. 1. Chemical Industry Press; pp. 2721Beijing: 2015
|
|
23
|
Wei D, Mei Y and Liu J: Quantification of
doxorubicin and validation of reversal effect of tea polyphenols on
multidrug resistance in human carcinoma cells. Biotechnol Lett.
25:291–294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han SO, Inui M and Yukawa H: Expression of
Corynebacterium glutamicum glycolytic genes varies with carbon
source and growth phase. Microbiology. 153:2190–2202. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Constable PA, Lawrenson JG, Dolman DE,
Arden GB and Abbott NJ: P-Glycoprotein expression in human retinal
pigment epithelium cell lines. Exp Eye Res. 83:24–30. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Braga F, Ayres-Saraiva D, Gattass CR and
Capella MA: Oleanolic acid inhibits the activity of the multidrug
resistance protein ABCC1 (MRP1) but not of the ABCB1
(P-glycoprotein): Possible use in cancer chemotherapy. Cancer Lett.
248:147–152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu ST, Chen TM, Tseng SY and Chen YH:
Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in
breast cancer cells. Biochem Biophys Res Commun. 358:79–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boháčová V, Sulová Z, Dovinová I, Dovinová
I, Poláková E, Barančík M, Uhrík B, Orlický J and Breier A: L1210
cells cultivated under the selection pressure of doxorubicin or
vincristine express common mechanisms of multidrug resistance based
on the overexpression of P-glycoprotein. Toxicol In Vitro.
20:1560–1568. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang H, Jing X, Wu X, Hu J, Zhang X, Wang
X, Su P, Li W and Zhou G: Suppression of multidrug resistance by
rosiglitazone treatment in human ovarian cancer cells through
downregulation of FZD1 and MDR1 genes. Anticancer Drugs.
26:706–715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yun M, Lee D, Park MN, Kim EO, Sohn EJ,
Kwon BM and Kim SH: Cinnamaldehyde derivative (CB-PIC) sensitizes
chemo-resistant cancer cells to drug-induced apoptosis via
suppression of MDR1 and its upstream STAT3 and AKT signaling. Cell
Physiol Biochem. 35:1821–1830. 2015. View Article : Google Scholar : PubMed/NCBI
|
